Overview

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).

Phase:

Phase 1

Details

Lead Sponsor:

Acerta Pharma BV

Treatments:

Acalabrutinib